Edwards Lifesciences Corporation (EW) has been facing lawsuits, significant stockholder losses, and a series of concerning developments. Reputable law firms are encouraging stockholders to contact them for information around their rights, and there appears to be a class action lawsuit for security frauds connected to the company. Traders have sold the company's stock due to concerns relate to growth expectations. In business operations, the company is preparing for its Q3 release, with revenue growth expected. Notably, Edwards Lifesciences recently sold its Critical Care Product Group for $4.2 billion to BD. This marks a significant event as BD aims to become a leader in advanced monitoring technology. Edwards Lifescmmmmompany has also commenced layoffs, and some analysts have made a severe cut to the firm's estimates for the next year. Despite some promising underlying earnings growth over the last three years and strong institutional ownership, the company's stockholders have seen an unfortunate 43% loss over that time. Edward's stock has also underperformed when compared to competitors. Nonetheless, the company's strong return on capital is just one of the highlights of its operational profile.
Edwards Lifesciences Corp EW News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 19 Oct 2024 15:28:28 GMT -
Rating -8
- Innovation 1
- Information 6
- Rumor -6
